Eli Lilly’s already-delayed new insulin has run into another roadblock, as potentially harmful liver side effects have sent the company back to the clinic, putting off a potential regulatory filing by a year or more and leading a top analyst to eulogize the program.

…read more

Source: Lilly’s new insulin is likely DOA after latest delay, analyst says


0 No comments